Display options
Cite
Sahay M, Saivani Y, Ismal K, et al. Mycophenolate versus Cyclophosphamide for Lupus Nephritis. Indian J Nephrol. 2018;28(1):35-40doi: 10.4103/ijn.IJN_2_16.
Sahay, M., Saivani, Y., Ismal, K., & Vali, P. S. (2018). Mycophenolate versus Cyclophosphamide for Lupus Nephritis. Indian journal of nephrology, 28(1), 35-40. https://doi.org/10.4103/ijn.IJN_2_16
Sahay, M, et al. "Mycophenolate versus Cyclophosphamide for Lupus Nephritis." Indian journal of nephrology vol. 28,1 (2018): 35-40. doi: https://doi.org/10.4103/ijn.IJN_2_16
Sahay M, Saivani Y, Ismal K, Vali PS. Mycophenolate versus Cyclophosphamide for Lupus Nephritis. Indian J Nephrol. 2018 Jan-Feb;28(1):35-40. doi: 10.4103/ijn.IJN_2_16. PMID: 29515299; PMCID: PMC5830807.
Copy Download .nbib Format: NLM
Share it on

Indian J Nephrol. 2018 Jan-Feb;28(1):35-40. doi: 10.4103/ijn.IJN_2_16.

Mycophenolate versus Cyclophosphamide for Lupus Nephritis.

Indian journal of nephrology

M Sahay, Y Saivani, K Ismal, P S Vali

Affiliations

  1. Department of Nephrology, Osmania General Hospital, Hyderabad, Telangana, India.

PMID: 29515299 PMCID: PMC5830807 DOI: 10.4103/ijn.IJN_2_16

Abstract

Systemic lupus erythematosus is common in our country, and renal involvement is an important cause of chronic kidney disease. This study was aimed at comparing the three regimens, i.e., cyclophosphamide-based regimes (low dose and high dose) and mycophenolate mofetil (MMF)-based regime and determining if cyclophosphamide (CPM)-based regime can be an effective, safe, and cheap alternative to MMF-based regime in a resource-limited setting. Out of 144 patients, females constituted 89%. Nephrotic nephritic presentation was the most common. Rapidly progressive renal failure was seen in in 42 (29.1%) patients. Class IV was the most common 66 (45.8%) histological class. Crescentic glomerulonephritis was seen in 18 (12.5%). Overall remission (complete + partial) at 6 months was seen in 71.4% in National Institute of Health regime, 65% in European lupus nephritis trial protocol and 72.9% in MMF regime. End-stage renal disease and switching to other therapies were comparable among the three groups. Although infections were more with CPM, the difference was not statistically significant. CPM-based therapies were associated with a significantly lower cost.

Keywords: Cyclophosphamide; induction; lupus nephritis; mycophenolate; systemic lupus erythematous; treatment

Conflict of interest statement

There are no conflicts of interest.

References

  1. Clin Nephrol. 2011 Mar;75(3):233-41 - PubMed
  2. Nephrology (Carlton). 2008 Dec;13(8):702-7 - PubMed
  3. J Am Soc Nephrol. 2009 May;20(5):1103-12 - PubMed
  4. Rheumatology (Oxford). 2007 Jul;46(7):1096-101 - PubMed
  5. Arthritis Rheum. 1992 Jun;35(6):630-40 - PubMed
  6. Ann Rheum Dis. 2012 Nov;71(11):1771-82 - PubMed
  7. N Engl J Med. 1978 Nov 23;299(21):1151-5 - PubMed
  8. Lupus. 2007;16(9):707-12 - PubMed
  9. N Engl J Med. 2005 Nov 24;353(21):2219-28 - PubMed
  10. Lancet. 1992 Sep 26;340(8822):741-5 - PubMed
  11. Kidney Int. 2004 Feb;65(2):521-30 - PubMed
  12. Indian J Nephrol. 2011 Jul;21(3):160-5 - PubMed
  13. N Engl J Med. 2000 Oct 19;343 (16):1156-62 - PubMed
  14. Kidney Int. 2016 Jan;89(1):235-42 - PubMed
  15. Am J Kidney Dis. 2013 Jan;61(1):74-87 - PubMed
  16. J Am Soc Nephrol. 2004 Feb;15(2):241-50 - PubMed
  17. Ann Intern Med. 1996 Oct 1;125(7):549-57 - PubMed
  18. Arthritis Care Res (Hoboken). 2012 Jun;64(6):797-808 - PubMed
  19. Arthritis Rheum. 2002 Aug;46(8):2121-31 - PubMed
  20. N Engl J Med. 1986 Mar 6;314(10):614-9 - PubMed

Publication Types